ClinicalTrials.gg
CompletedNCT04849416Updated Feb 6, 2026Results posted

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

A Phase 2 interventional study of LOXO-305 in Leukemia, Lymphoid, Lymphoma, Non-Hodgkin and Lymphoma, Mantle-Cell, sponsored by Eli Lilly and Company. Completed at 22 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Primary conditionLeukemia, Lymphocytic, Chronic, B-CellRegistry: Leukemia, LymphoidReclassifiedWhy we changed it
Registry
Leukemia, Lymphoid — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Lymphocytic, Chronic, B-Cell
Why
  1. The study's listed conditions name Leukemia, Lymphocytic, Chronic, B-Cell, a narrower term within Leukemia, Lymphoid.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 14 open to participants now, 19 under way, 6 of them phase 3. pirtobrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
12th of 23
87 · median 87
Started
2021
with 3 others
Phase 2
11 of 23
7 open now
Registered
3rd of 23
by date
Lead sponsor
5 of 23
Eli Lilly and Company

Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 12th largest by enrollment, is one of 4 that started in 2021, is one of 11 in phase 2, and was the 3rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

14 of the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About pirtobrutinib

pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.

03

Conditions studied

  • Leukemia, Lymphoid
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Mantle-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, B-Cell
  • Lymphoma, B-Cell, Marginal Zone
  • Leukemia, Lymphocytic, Chronic, B-Cell
04

In context

Leukemia, Lymphocytic, Chronic, B-Cell Reclassified

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

This study's enrollment of 87 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Leukemia, Lymphocytic, Chronic, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Lymphoid. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with confirmed B-cell including:

    • Mantle cell lymphoma (MCL) treated with a prior Bruton's tyrosine kinase (BTK) inhibitor containing regimen;
    • CLL/SLL treated with a prior BTK inhibitor containing regimen;
    • Other types of B-cell NHL
  • All participants must have disease requiring treatment, for CLL/SLL participants, at least 1 indication for treatment consistent with IWCLL 2018 criteria is required
  • 0-2
  • Adequate hematologic status, coagulation, hepatic and renal function

Exclusion criteria

Exclusion Criteria

  • Lack of adequate for agent or anticancer therapy, major surgery, and radiotherapy prior to the first dose of study treatment
  • Participants requiring therapeutic anticoagulation with warfarin
  • Known central nervous system (CNS) involvement by systemic lymphoma. Primary CNS lymphoma is excluded
  • Significant cardiovascular disease
  • Prolongation of the
  • Test positive for (HIV)
  • Current treatment with certain strong cytochrome P450 3A4 (CYP450 3A4) inhibitors or inducers and/or strong p-glycoprotein (P-gp) inhibitors
  • Pregnancy or lactation
  • Active second
  • Prior treatment with LOXO-305
  • Known to any component or of LOXO-305
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    LOXO-305

    Participants received 200 mg of LOXO-305 administered orally once daily (QD) on Days 1 through 28 of a 28-day cycle. The treatment was continued until progressive disease, a discontinuation criterion, or unacceptable toxicity.

    Drug: LOXO-305

Interventions

  • Administered orally.

    Also known as: LY3527727, Pirtobrutinib

07

What researchers measure

Primary outcomes

  1. Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee

    ORR was assessed by an Independent Review Committee (IRC). It was estimated based on the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR). Two-sided 95% CI was calculated using the exact binomial distribution. PAS consisted of participants with Central histologically confirmed non-blastoid MCL, with no CNS metastases and treated with prior chemoimmunotherapy and BTK inhibitor-containing regimen, measurable disease at baseline as assessed using Lugano criteria, and have received at least 1 dose of study drug.

    Time frame: Date of First Dose to Date of Disease Progression or Subsequent Anti-cancer Therapy (up to 100 Weeks)

Secondary outcomes

  1. PAS ORR: ORR Assessed by Investigator

    ORR was assessed by the Investigator. It was estimated based on the percentage of participants with BOR of CR or PR. Two-sided 95% CI was calculated using the exact binomial distribution.

    Time frame: Date of First Dose to Date of Disease Progression or Subsequent Anti-cancer Therapy (up to 100 Weeks)

  2. PAS Best Overall Response (BOR): Percentage of Participants With CR, PR, Stable Disease (SD), Progressive Disease (PD) or Not Evaluable (NE)

    BOR was assessed by the IRC and Investigator. Best overall assessment categories include (in descending order of extent of response): CR, PR, SD, PD, and NE. Two-sided 95% CI was calculated using the exact binomial distribution.

    Time frame: Date of First Dose to Date of Disease Progression or Subsequent Anti-cancer Therapy (up to 100 Weeks)

  3. PAS: Duration of Response (DOR)

    DOR was assessed by the Investigator and IRC. DOR is defined as the number of months from the date of the first documented response to the date of PD or death, whichever occurs earlier. Participants who are alive and without documented PD as of data analysis cutoff date will be censored.

    Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 100 Weeks)

  4. PAS: Progression Free Survival (PFS)

    PFS was assessed by the IRC and Investigator. PFS is defined as the number of months from the date of the first dose of study drug to the earlier of documented PD or death due to any cause. Participants who are alive and without documented PD as of data analysis cutoff date were censored.

    Time frame: Date of First Dose to Progressive Disease or Death from Any Cause (Up to 100 weeks)

  5. PAS: Overall Survival (OS)

    OS is defined as the number of months elapsed between the date of the first dose of study drug and the date of death from any cause. Participants who are alive or lost to follow-up as of the data cutoff date will be censored.

    Time frame: Date of First Dose to Date of Death from Any Cause (Up to 100 weeks)

  6. Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration(AUC[0-tlast] of LOXO-305

    PK: AUC\[0-tlast\] of LOXO-305

    Time frame: Cycle 1 Day 1: Predose, 1, 2, 4, 8, 12, 24 hours(h) postdose; Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 h postdose; Cycle 2 Day 1: Predose, 1, 2, 4, 8, 24 h postdose; Cycle 4 Day 1: Predose, 1, 2, 4, 8 h postdose.

  7. PK: Maximum Concentration (Cmax) of LOXO-305

    PK: Cmax of LOXO-305

    Time frame: Cycle 1 Day 1: Predose, 1, 2, 4, 8, 12, 24 hours(h) postdose; Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 h postdose; Cycle 2 Day 1: Predose, 1, 2, 4, 8, 24 h postdose; Cycle 4 Day 1: Predose, 1, 2, 4, 8 h postdose.

  8. PAS: Change From Baseline in Disease-Related Symptoms and Health-Related Quality of Life (HRQoL) Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms.

    Time frame: Baseline, 7 Days After Treatment Discontinuation (Up To 100 Weeks)

08

Results

Posted Jul 16, 2024

Participant flow

Participant flow — Overall Study
MilestoneMantle Cell Lymphoma (MCL) CohortChronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) CohortOther Cohort
Started391731
Received at least one dose of study drug391731
Completed18317
Not completed211414
Withdrew: Ongoing treatment1253
Withdrew: On post-treatment follow-up8910
Withdrew: Withdrawal by subject001
Withdrew: Lost to follow-up100

Outcome measures

PrimaryPrimary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee

ORR was assessed by an Independent Review Committee (IRC). It was estimated based on the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR). Two-sided 95% CI was calculated using the exact binomial distribution. PAS consisted of participants with Central histologically confirmed non-blastoid MCL, with no CNS metastases and treated with prior chemoimmunotherapy and BTK inhibitor-containing regimen, measurable disease at baseline as assessed using Lugano criteria, and have received at least 1 dose of study drug.

Time frame:
Date of First Dose to Date of Disease Progression or Subsequent Anti-cancer Therapy (up to 100 Weeks)
Reported as:
Number · Percentage of participants
Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee
Percentage of participantsPAS - MCL Group
Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee71.4 (51.3 to 86.8)
SecondaryPAS ORR: ORR Assessed by Investigator

ORR was assessed by the Investigator. It was estimated based on the percentage of participants with BOR of CR or PR. Two-sided 95% CI was calculated using the exact binomial distribution.

Time frame:
Date of First Dose to Date of Disease Progression or Subsequent Anti-cancer Therapy (up to 100 Weeks)
Reported as:
Number · Percentage of participants
PAS ORR: ORR Assessed by Investigator
Percentage of participantsPAS - MCL Group
PAS ORR: ORR Assessed by Investigator64.3 (44.1 to 81.4)
SecondaryPAS Best Overall Response (BOR): Percentage of Participants With CR, PR, Stable Disease (SD), Progressive Disease (PD) or Not Evaluable (NE)

BOR was assessed by the IRC and Investigator. Best overall assessment categories include (in descending order of extent of response): CR, PR, SD, PD, and NE. Two-sided 95% CI was calculated using the exact binomial distribution.

Time frame:
Date of First Dose to Date of Disease Progression or Subsequent Anti-cancer Therapy (up to 100 Weeks)
Reported as:
Number · Percentage of participants
PAS Best Overall Response (BOR): Percentage of Participants With CR, PR, Stable Disease (SD), Progressive Disease (PD) or Not Evaluable (NE)
Percentage of participantsPAS - MCL Group
CR by IRC14.3 (4.00 to 32.7)
PR by IRC57.1 (37.2 to 75.5)
SD by IRC7.1 (0.9 to 23.5)
PD by IRC14.3 (4.0 to 32.7)
NE by IRC7.1 (0.9 to 23.5)
CR by Investigator14.3 (4.0 to 32.7)
PR by Investigator50.0 (30.7 to 69.4)
SD by Investigator10.7 (2.3 to 28.2)
PD by Investigator17.9 (6.1 to 36.9)
NE by Investigator7.1 (0.9 to 23.5)
SecondaryPAS: Duration of Response (DOR)

DOR was assessed by the Investigator and IRC. DOR is defined as the number of months from the date of the first documented response to the date of PD or death, whichever occurs earlier. Participants who are alive and without documented PD as of data analysis cutoff date will be censored.

Time frame:
Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 100 Weeks)
Reported as:
Median · Months
PAS: Duration of Response (DOR)
MonthsPAS - MCL Group
IRC AssessmentNA (4.83 to NA)
Investigator Assessment11.50 (3.68 to NA)
SecondaryPAS: Progression Free Survival (PFS)

PFS was assessed by the IRC and Investigator. PFS is defined as the number of months from the date of the first dose of study drug to the earlier of documented PD or death due to any cause. Participants who are alive and without documented PD as of data analysis cutoff date were censored.

Time frame:
Date of First Dose to Progressive Disease or Death from Any Cause (Up to 100 weeks)
Reported as:
Median · Months
PAS: Progression Free Survival (PFS)
MonthsPAS - MCL Group
IRC Assessment9.43 (5.32 to NA)
Investigator Assessment6.80 (3.61 to 13.34)
SecondaryPAS: Overall Survival (OS)

OS is defined as the number of months elapsed between the date of the first dose of study drug and the date of death from any cause. Participants who are alive or lost to follow-up as of the data cutoff date will be censored.

Time frame:
Date of First Dose to Date of Death from Any Cause (Up to 100 weeks)
Reported as:
Median · Months
PAS: Overall Survival (OS)
MonthsPAS - MCL Group
PAS: Overall Survival (OS)15.47 (8.67 to NA)
SecondaryPharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration(AUC[0-tlast] of LOXO-305

PK: AUC\[0-tlast\] of LOXO-305

Time frame:
Cycle 1 Day 1: Predose, 1, 2, 4, 8, 12, 24 hours(h) postdose; Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 h postdose; Cycle 2 Day 1: Predose, 1, 2, 4, 8, 24 h postdose; Cycle 4 Day 1: Predose, 1, 2, 4, 8 h postdose.
Reported as:
Geometric mean · nanogram hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration(AUC[0-tlast] of LOXO-305
nanogram hour per milliliter (ng*h/mL)200 mg LOXO-305 QD
Cycle 1 Day 162700 ± 15.0
Cycle 1 Day 8123000 ± 38.1
Cycle 2 Day 1137000 ± 28.7
Cycle 4 Day 146600 ± 20.0
SecondaryPK: Maximum Concentration (Cmax) of LOXO-305

PK: Cmax of LOXO-305

Time frame:
Cycle 1 Day 1: Predose, 1, 2, 4, 8, 12, 24 hours(h) postdose; Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 h postdose; Cycle 2 Day 1: Predose, 1, 2, 4, 8, 24 h postdose; Cycle 4 Day 1: Predose, 1, 2, 4, 8 h postdose.
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of LOXO-305
nanograms per milliliter (ng/mL)200 mg LOXO-305 QD
Cycle 1 Day 14800 ± 14.7
Cycle 1 Day 88380 ± 35.3
Cycle 2 Day 19080 ± 22.3
Cycle 4 Day 17890 ± 22.5
SecondaryPAS: Change From Baseline in Disease-Related Symptoms and Health-Related Quality of Life (HRQoL) Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms.

Time frame:
Baseline, 7 Days After Treatment Discontinuation (Up To 100 Weeks)
Reported as:
Mean · score on a scale
PAS: Change From Baseline in Disease-Related Symptoms and Health-Related Quality of Life (HRQoL) Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
score on a scalePAS - MCL Group
Global health status2.5 ± 4.78
Functional scale: Physical functioning0.8 ± 2.96
Functional scale: Role functioning-2.9 ± 3.57
Functional scale: Emotional functioning-2.0 ± 1.68
Functional scale: Cognitive functioning-1.0 ± 1.73
Functional scale: Social functioning-7.8 ± 3.81
Symptom scale: Fatigue-1.3 ± 3.80
Symptom scale: Nausea and vomiting0.0 ± 1.43
Symptom scale: Pain-3.9 ± 2.27
Symptom scale: Dyspnea-2.0 ± 1.96
Symptom scale: Insomnia2.0 ± 3.47
Symptom scale: Appetite loss-2.0 ± 4.49
Symptom scale: Constipation-3.9 ± 2.68
Symptom scale: Diarrhea0.0 ± 0.00
Symptom scale: Financial difficulties3.9 ± 4.85

Adverse events

Collected over Baseline Up To 100 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg LOXO-305 QD37/87 (42.5%)33/87 (37.9%)81/87 (93.1%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
Event200 mg LOXO-305 QD
PneumoniaInfections and infestations4/87
Covid-19Infections and infestations3/87
DeathGeneral disorders2/87
BronchitisInfections and infestations2/87
Covid-19 pneumoniaInfections and infestations2/87
MyelosuppressionBlood and lymphatic system disorders1/87
NeutropeniaBlood and lymphatic system disorders1/87
ThrombocytopeniaBlood and lymphatic system disorders1/87
Acute myocardial infarctionCardiac disorders1/87
Ventricular extrasystolesCardiac disorders1/87
Most frequent other events
Showing 10 of 45
Most frequent other events
Event200 mg LOXO-305 QD
AnaemiaBlood and lymphatic system disorders27/87
Neutrophil count decreasedInvestigations26/87
Blood bilirubin increasedInvestigations20/87
HypokalaemiaMetabolism and nutrition disorders20/87
White blood cell count decreasedInvestigations19/87
HyperuricaemiaMetabolism and nutrition disorders17/87
Covid-19Infections and infestations14/87
Aspartate aminotransferase increasedInvestigations14/87
HyperglycaemiaMetabolism and nutrition disorders14/87
PyrexiaGeneral disorders13/87

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)MCL CohortCLL/SLL CohortOther CohortTotal
Mean64.1 ± 7.460.8 ± 9.259.9 ± 9.962.0 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)MCL CohortCLL/SLL CohortOther CohortTotal
Female1261331
Male27111856
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MCL CohortCLL/SLL CohortOther CohortTotal
Hispanic or Latino0000
Not Hispanic or Latino0000
Unknown or Not Reported39173187
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MCL CohortCLL/SLL CohortOther CohortTotal
American Indian or Alaska Native0000
Asian39173187
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)MCL CohortCLL/SLL CohortOther CohortTotal
China39173187
09

Study locations

22 sites
  • Wannan Medical College Yijishan Hospital
    Wuhu, Anhui 241001, China
  • Beijing Cancer hospital
    Beijing, Beijing Municipality 100142, China
  • Southern Medical University Nanfang Hospital
    Guangzhou, Guangdong 510515, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 511400, China
  • Hainan General Hospital
    Haikou, Hainan 570311, China
  • Affiliated Hospital of Hebei University
    Baoding, Hebei 71066, China
  • Xingtai People's Hospital
    Xingtai, Hebei 054031, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • The First Affiliated Hospital of Henan University of Science &Technology
    Luoyang Shi, Henan 471003, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210000, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215066, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Xi'an International Medical Center Hospital
    Xi'an, Shaanxi 710126, China
  • Sichuan Cancer Hospital
    Chengdu, Sichuan 610041, China
  • Institute of hematology&blood disease hospital
    Tianjin, Tianjin Municipality 300020, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
  • Xinjiang Medical University Cancer Hospital - Urumqi
    Ürümqi, Xinjiang 830000, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • Shanghai East Hospital
    Shanghai, 200120, China
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting

Access criteria: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting

Data sharing details ↗ · vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Apr 2023, 22 months.

Results were first posted in Jul 2024, 1 year 3 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 22 months is below that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2021
First posted
Apr 19, 2021
StartActual
May 14, 2021
Primary completionActual
Apr 10, 2023
CompletionActual
Dec 29, 2025
Results first posted
Jul 16, 2024
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04849416
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Apr 19, 2021
Start date
May 14, 2021
Primary completion
Apr 10, 2023
Completion
Dec 29, 2025
Results posted
Jul 16, 2024
Last update
Feb 6, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion